研究者総覧

浅野 岳晴 (アサノ タケハル)

  • 総合医学第1講座 講師
Last Updated :2021/09/22

研究者情報

ホームページURL

J-Global ID

研究分野

  • ライフサイエンス / 消化器内科学

経歴

  • 自治医大さいたま医療センター

研究活動情報

論文

  • Shuhei Yoshikawa, Takeharu Asano, Mina Morino, Keita Matsumoto, Hitomi Kashima, Yudai Koito, Takaya Miura, Yuko Takahashi, Rumiko Tsuboi, Takehiro Ishii, Haruka Otake, Junichi Fujiwara, Masanari Sekine, Takeshi Uehara, Kazuhito Yuhashi, Satohiro Matsumoto, Shinichi Asabe, Hiroyuki Miyatani, Hirosato Mashima
    Scientific reports 11 1 3015 - 3015 2021年02月 
    Pruritus is known to be a common complication in hepatitis patients, but the exact frequency and degree are not fully elucidated. Thus, we evaluated pruritus of 450 patients with chronic liver disease at our hospital. Pruritus was observed in 240 (53%) of the patients. Pruritus was significantly associated with males (OR = 1.51, P = 0.038) and patients with alkaline phosphatase (ALP) ≥ 200 U/L (OR = 1.56, P = 0.0495) and was significantly less in HBsAg-positive patients (OR = 0.449, P = 0.004). Seasonally, there was no difference in the frequency of pruritus between summer and winter. Of the 24 refractory pruritus patients treated with nalfurafine, 17 (71%) indicated improvement of itch, which is defined as a decrease in the visual analog scale score ≥ 30 mm. Pruritus was improved by nalfurafine both during daytime and nighttime in the Kawashima's scores evaluation. All patients who received nalfurafine exhibited improved Kawashima's scores ≥ 1 point during the daytime or nighttime. In conclusion, pruritus occurred in > 50% of patients with chronic liver disease, and predictors of pruritus were males and ALP ≥ 200 U/L. Nalfurafine may be useful for pruritus, regardless of whether daytime or nighttime.
  • Yoshinari Takaoka, Kouichi Miura, Naoki Morimoto, Tadashi Ikegami, Satoru Kakizaki, Ken Sato, Takashi Ueno, Atsushi Naganuma, Takashi Kosone, Hirotaka Arai, Takeshi Hatanaka, Toshiyuki Tahara, Shigeo Tano, Takaaki Ohtake, Toshimitsu Murohisa, Masashi Namikawa, Takeharu Asano, Toshiro Kamoshida, Katsuhiko Horiuchi, Takeshi Nihei, Atsuko Soeda, Hidekazu Kurata, Takeshi Fujieda, Toshiya Ohtake, Yukimura Fukaya, Makoto Iijima, Shunji Watanabe, Norio Isoda, Hironori Yamamoto
    Hepatology research : the official journal of the Japan Society of Hepatology 51 1 51 - 61 2021年01月 
    AIM: This study aimed to evaluate the real-world efficacy and safety of 12-week sofosbuvir/velpatasvir (SOF/VEL) treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus (HCV) infection. METHODS: A total 72 of patients with Child-Pugh (CP) class B or C were enrolled. We evaluated the sustained virologic response at 12 weeks after the end of treatment (SVR12), adverse events (AEs), and changes in the liver function. RESULTS: All participants had genotype 1 or 2 HCV infection. At baseline, the numbers of patients with CP class B and C were 59 and 13, respectively. The overall SVR12 rate was 95.8% (69/72); 94.9% (56/59) in CP class B and 100% (13/13) in CP class C. The serum albumin level, prothrombin time and ascites were significantly improved (P < 0.01); however, the serum bilirubin level and encephalopathy did not improve. Among patients who achieved SVR12, 75.0% showed an improvement in their CP score, while 5.9% showed a worsening. The presence of large portosystemic shunt (diameter ≥6 mm) and hyperbilirubinemia (≥2.0 mg/dL) were independent factors that interfered with the improvement in the CP score (P < 0.05). The most common AEs were encephalopathy (15.3%) and skin symptoms (7.9%). Two patients discontinued SOF/VEL due to AEs. CONCLUSIONS: Treatment with SOF/VEL for 12 weeks was relatively safe and effective for patients with decompensated cirrhosis. An SVR provided an improvement of the liver function in the majority of patients. However, large portosystemic shunt and hyperbilirubinemia were independent factors that interfered with the improvement in the CP score.
  • A型肝炎の炎症改善後も黄疸遷延した1例
    小島 柊, 浅野 岳晴, 吉川 修平, 大竹 はるか, 藤原 純一, 関根 匡成, 上原 健志, 湯橋 一仁, 松本 吏弘, 宮谷 博幸, 眞嶋 浩聡
    埼玉県医学会雑誌 54 1 220 - 223 埼玉県医学会 2019年12月 [査読有り][通常論文]
  • Shuhei Yoshikawa, Takeharu Asano, Mizuki Watanabe, Takehiro Ishii, Haruka Ohtake, Junichi Fujiwara, Masanari Sekine, Takeshi Uehara, Kohei Hamamoto, Kazuhito Yuhashi, Satohiro Matsumoto, Shinichi Asabe, Hiroyuki Miyatani, Katsuhiko Matsuura, Hirosato Mashima
    Internal medicine (Tokyo, Japan) 58 18 2639 - 2643 2019年09月 [査読有り][通常論文]
     
    An 83-year-old man with a history of carbon ion radiotherapy for hepatocellular carcinoma nine years ago presented to a primary care hospital with a fever and abdominal pain. He underwent computed tomography, which revealed the rupture of a hepatic pseudoaneurysm close to the fiducial marker for carbon ion radiotherapy and bleeding into the bile duct. He was successfully treated with transcatheter arterial embolization. Thereafter, re-rupture occurred from a site proximal to the first rupture, and this was treated similarly. It is necessary to be alert for not only tumor recurrence but also pseudoaneurysm occurrence after carbon ion radiotherapy.
  • Takeharu Asano, Naoto Kubota, Norihiro Koizumi, Kazunori Itani, Tsuyoshi Mitake, Kazuhito Yuhashi, Hongen Liao, Mamoru Mitsuishi, Shigemi Takeishi, Toshiaki Takahashi, Shin Ohnishi, Shiro Sasaki, Ichiro Sakuma, Takashi Kadowaki
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY 2017年 [査読有り][通常論文]
     
    Objectives. To evaluate the abdominal visceral fat area (VFA), we developed novel ultrasonographic (US) methods for estimating. Methods. 100 male volunteers were recruited, and their VFA was calculated by two novel US methods, the triangle method and the ellipse method. The VFA calculated by these methods was compared with the VFA calculated by CT. Results. Both the VFA calculated by the triangle method (r = 0 766, p < 0 001) and the ellipse method (r = 0 781, p < 0 001) showed a high correlation coefficient with the VFA calculated by CT. Also, the VFA calculated by our novel methods were significantly increased in subjects with one or more metabolic risk factors than in those without any risk factors. Furthermore, the correlation coefficients obtained using the two methods were enhanced by the addition of multiple regression analysis (with the triangle method, r = 0 8586, p < 0 001; with the ellipse method, r = 0 8642, p < 0 001). Conclusions. The VFA calculated by the triangle or ellipse method showed a high correlation coefficient with the VFA calculated by CT. These US methods are easy to use, they involve no radiation exposure, and the measurements can be conducted frequently. We hope that our simple methods would be widely adopted for the evaluation of VFA.
  • Ikuo Nakamura, Takeharu Asano, Shinichi Asabe, Mayumi Ando, Takatomo Sano, Yuki Miyata, Junichi Taira, Katsutoshi Sugimoto, Yasuharu Imai, Fuminori Moriyasu, Michio Imawari
    Hepatology research : the official journal of the Japan Society of Hepatology 45 1 107 - 12 2015年01月 [査読有り][通常論文]
     
    AIM: The combination therapy of pegylated interferon-α and ribavirin (PEG IFN/RBV) is one of the effective treatments for chronic hepatitis C (CHC) patients. Natural killer (NK)-cell activity was reported to be impaired in patients with hepatitis C virus (HCV). The aim of this study was to examine whether PEG IFN/RBV therapy could restore NK activity in CHC patients. METHODS: In 19 CHC patients, PEG IFN/RBV therapy was performed. Just before (0M), at 3 months of the therapy (3M) and at 6 months after completion of the therapy (6M), NK activity and the frequency of NK cells, CD56(dim) NK cells and CD56(bright) NK cells in peripheral blood was estimated by creatinine release assay and flow cytometry. Statistical analysis was performed by anova and Mann-Whitney U-test. RESULTS: anova showed that NK activity significantly improved at 6M (vs 0M, P < 0.05) in the patients studied and in the patients with sustained virological response (SVR). It also showed that frequency of CD56(bright) NK cells was significantly increased at 6M (vs 0M, P < 0.05) in the patients studied and in the SVR group. However, no significant change in NK activity and frequency of CD56(bright) NK cells were detected in non-SVR group. Furthermore, NK activity ratio (6M/0M) in the SVR group was revealed to be higher compared with that in the non-SVR group by analysis using Mann-Whitney U-test (P < 0.05). CONCLUSION: PEG IFN/RBV therapy in CHC patients could improve NK activity by increasing the frequency of CD56(bright) NK cells in SVR patients. Our study also revealed that eradication of HCV could restore NK-cell activity.
  • Tomoko Yamazaki, Mayumi Mori, Satoko Arai, Ryosuke Tateishi, Masanori Abe, Mihoko Ban, Akemi Nishijima, Maki Maeda, Takeharu Asano, Toshihiro Kai, Kiyohiro Izumino, Jun Takahashi, Kayo Aoyama, Sei Harada, Toru Takebayashi, Toshiaki Gunji, Shin Ohnishi, Shinji Seto, Yukio Yoshida, Yoichi Hiasa, Kazuhiko Koike, Ken-ichi Yamamura, Ken-ichiro Inoue, Toru Miyazaki
    PloS one 9 10 e109123  2014年 
    BACKGROUND: Hepatocellular carcinoma (HCC), the fifth most common cancer type and the third highest cause of cancer death worldwide, develops in different types of liver injuries, and is mostly associated with cirrhosis. However, non-alcoholic fatty liver disease often causes HCC with less fibrosis, and the number of patients with this disease is rapidly increasing. The high mortality rate and the pathological complexity of liver diseases and HCC require blood biomarkers that accurately reflect the state of liver damage and presence of HCC. METHODS AND FINDINGS: Here we demonstrate that a circulating protein, apoptosis inhibitor of macrophage (AIM) may meet this requirement. A large-scale analysis of healthy individuals across a wide age range revealed a mean blood AIM of 4.99 ± 1.8 µg/ml in men and 6.06 ± 2.1 µg/ml in women. AIM levels were significantly augmented in the younger generation (20s-40s), particularly in women. Interestingly, AIM levels were markedly higher in patients with advanced liver damage, regardless of disease type, and correlated significantly with multiple parameters representing liver function. In mice, AIM levels increased in response to carbon tetrachloride, confirming that the high AIM observed in humans is the result of liver damage. In addition, carbon tetrachloride caused comparable states of liver damage in AIM-deficient and wild-type mice, indicating no influence of AIM levels on liver injury progression. Intriguingly, certain combinations of AIM indexes normalized to liver marker score significantly distinguished HCC patients from non-HCC patients and thus could be applicable for HCC diagnosis. CONCLUSION: AIM potently reveals both liver damage and HCC. Thus, our results may provide the basis for novel diagnostic strategies for this widespread and fatal disease.
  • Junchen Wang, You Zhou, Norihiro Koizumi, Naoto Kubota, Takeharu Asano, Kuzuhito Yuhashi, Tsuyoshi Mitake, Kazunori Itani, Toshiaki Takahashi, Shigemi Takeishi, Shiro Sasaki, Takashi Kadowaki, Ichiro Sakuma, Hongen Liao
    2013 35TH ANNUAL INTERNATIONAL CONFERENCE OF THE IEEE ENGINEERING IN MEDICINE AND BIOLOGY SOCIETY (EMBC) 2013 6486 - 6489 2013年 [査読有り][通常論文]
     
    Ultrasonography-based visceral fat estimation is a promising method to assess central obesity, which is associated with metabolic syndrome. The key to this method is to measure three types of distance in the ultrasound image. The most important one is the distance from the skin surface to the posterior wall of the abdominal aorta. We present a novel automatic measurement method to calculate this distance using 1D ultrasound signal processing. It is different from the conventional 2D image processing based methods which have high failure rate when the target is blurred or partially imaged. The proposed method identifies the waveforms of the aorta along a group of ultrasound scan lines and a rating mechanism is introduced to choose the best waveform for distance calculation. The robustness and accuracy of the method were evaluated by experiments based on clinical data.
  • Yuji Shindo, Hiroyuki Miyatani, Takeshi Uehara, Takashi Ikeya, Kenichi Yamanaka, Masatoshi Ikeda, Kouichi Tokai, Shinya Ushimaru, Satohiro Matsumoto, Takeharu Asano, Toru Takamatsu, Masanori Fukunishi, Takaaki Iwaki, Yoshinori Sagihara, Shinichi Asabe, Yukio Yoshida
    Journal of Japanese Society of Gastroenterology 109 7 1243 - 1249 2012年07月 [査読有り][通常論文]
     
    A 78-year-old man with hepatocellular carcinoma treated by chemoembolization and percutaneous ethanol injection was admitted to our hospital because of acute abdomen. The CT scan showed biliary fistula caused by hepatocellular carcinoma protruding from S3. Endoscopic retrograde cholangiopancreatography showed disruption of an intrahepatic duct and the main pancreatic duct, and contrast agent leaked into the peritoneal cavity from each duct Omental panniculitis with biliary fistula and pancreatic fistula was diagnosed. The symptoms improved by endoscopic nasobiliary drainage and endoscopic pancreatic stenting. On the 13th day after admission, we added endoscopic nasopancreatic drainage because his abdominal pain had been exacerbated by pancreatic juice leakage. Omental panniculitis by hepatocellular carcinoma complicated by biliary fistula and pancreatic fistula is extremely rare. Endoscopic transpapillary pancreaticobiliary drainage was effective for omental panniculitis in this case.
  • 浅野 岳晴, 中村 郁夫, 岡島 真里, 山中 健一, 浅部 伸一, 宮谷 博幸, 松浦 克彦, 吉田 行雄, 井廻 道夫
    肝臓 53 1 55 - 63 一般社団法人 日本肝臓学会 2012年01月 [査読無し][通常論文]
     
    症例は73歳,男性.C型慢性肝炎にて当院通院中であった.1999年,肝細胞癌(S5単発,径3 cm)が認められ肝右葉前区域切除術を施行した.術後は4-6カ月ごとに腹部USおよびCT検査にて経過観察していた.2009年3月の腹部CT検査にて,肝右葉の手術断端に,内部が不均一で一部造影効果を示す病変が認められた.同病変は同年5月のCTにて増大傾向を認め,仮性動脈瘤と診断された.腹部血管造影では,右肝動脈の前区域枝起始部に3 cm大の仮性動脈瘤を認めた.破裂予防のため,瘤のコイル塞栓術を施行した. 仮性動脈瘤の破裂の頻度や破裂後の死亡率は高率であるため,より早期の治療が望ましいとされている.また肝癌術後の画像フォローでは,術後晩期においても再発腫瘍の有無のみならず,動脈瘤や血栓などの血管変化にも留意する必要があると考えられた.
  • Takeharu Asano, Kiyotaka Watanabe, Naoto Kubota, Toshiaki Gunji, Masao Omata, Takashi Kadowaki, Shin Ohnishi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 24 10 1669 - 1676 2009年10月 [査読有り][通常論文]
     
    Background and Aim: Low levels of serum adiponectin have been reported to be associated with obesity, diabetes, and non-alcoholic steatohepatitis (NASH), as well as several malignancies. Adiponectin knockout (KO) mice have been reported to cause insulin resistance and neointimal formation of the artery. We used adiponectin KO mice fed a high fat (HF) diet, and investigated the effect of adiponectin on the progression of steatohepatitis and carcinogenesis in vivo. Methods: Adiponectin KO mice and wild type (WT) mice were fed a HF diet or normal chow for the periods of 24 and 48 weeks. The HF diet contained 60% of calories from fat. Results: The adiponectin KO mice on the HF diet showed obesity, marked elevation of serum transaminase levels, and hyperlipidemia. At 24 weeks, hepatic expression of tumor necrosis factor-alpha and procollagen alpha (I) was higher in KO mice as compared with WT mice. At 48 weeks, liver triglyceride contents in KO mice on normal chow were significantly higher than those in WT mice. Hepatocyte ballooning, spotty necrosis, and pericellular fibrosis around central veins were observed in KO mice on the HF diet. The pericellular fibrosis was more severe in KO mice on the HF diet than that in WT mice (1.62% vs 1.16%, P = 0.033). Liver adenoma and hyperplastic nodules developed in a KO mouse on the HF diet at 48 weeks (12.5%, n = 1/8), whereas no tumor was detected in WT mice (n = 10). Conclusions: Adiponectin may play a protective role in the progression of NASH in the early stages by suppressing tumor necrosis factor-alpha expression and liver fibrosis.
  • 高田 宗典, 浅野 岳晴, 八木岡 浩, 三好 秀征, 赤松 雅俊, 光井 洋, 郡司 俊秋, 椎名 秀一朗, 小俣 政男, 秋山 達
    日本内科学会雑誌 96 1 144 - 146 社団法人 日本内科学会 2007年01月 [査読無し][通常論文]
     
    脂肪肉腫は大腿や後腹膜に好発するwhite adipose tissueの悪性腫瘍で,高率に再発,血行性転移がみられる.患者は60歳男性.化学療法と手術を施行し原発巣は十分にcontrolされていたが,肝に転移巣が出現した.病変は肝内に限局し,化学療法抵抗性を示したため,radiofrequency ablation(RFA)治療を行い,焼灼十分を確認した.転移性肝癌に対しても,化学療法等と組み合わせた集学的治療の一環として,RFAが有効な手段になると考えた.
  • Takata M, Asano T, Yagioka H, Miyoshi H, Akamatsu M, Mitsui H, Gunji T, Shiina S, Akiyama T, Omata M
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 96 144 - 146 1 2007年01月 [査読有り][通常論文]
  • Asano Takeharu, Watanabe Kiyotaka, Kubota Naoto, Gunji Toshiaki, Kanamori Hiroshi, Ohnishi Shin, Omata Masao, Kadowaki Takashi
    HEPATOLOGY 44 4 661A - 662A 2006年10月 [査読有り][通常論文]
  • M Sasaki, H Funayama, T Asano, K Kasono, K Namai, H Tamemoto, S Ueno, M Ota, M Kawakami, S Shinoda, SE Ishikawa
    ENDOCRINE JOURNAL 50 5 501 - 506 2003年10月 [査読有り][通常論文]
     
    The present study reports a rare case of full-blown Cushing's disease several years after an episode of pituitary apoplexy. A 60 year-old woman complained of muscular weakness and generalized malaise. Ten years ago she had an episode of pituitary apoplexy. Diabetes mellitus was diagnosed at age 56, and thereafter she had been controlled her plasma glucose with diet therapy and oral hypoglycemic agents. She exhibited cushingoid feature of moon face and central obesity. Both plasma ACTH and serum cortisol levels were elevated to 170 pg/ml and 19.6 mug/dl, respectively. Dexamethasone suppression test showed that a large dose of 8 mg dexamethasone, but not a small dose of 2 mg, suppressed the pituitary-adrenocortical axis. CRE and methyrapone caused increases in plasma ACTH and serum cortisol levels. Brain T-1-weighted magnetic resonance imaging depicted a low signal of pituitary tumor, which was not enhanced by gadolinium. The pituitary tumor was removed by transsphenoidal adenomectomy, and immunohistochemistry revealed an ACTH-producing adenoma. The evidence suggested the possibility that the two pituitary tumors with dormant period of several years were a recurrence of ACTH-producing tumors in the present patient.

MISC

産業財産権



Copyright © MEDIA FUSION Co.,Ltd. All rights reserved.